• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Vaxxinity Inc.

    4/27/22 5:03:00 PM ET
    $VAXX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VAXX alert in real time by email
    SC 13G 1 d334219dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

     

     

    Vaxxinity, Inc.

    (Name of Issuer)

    Class A Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    92244V104

    (CUSIP Number)

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications:

    W. Bruce Newsome, Esq.

    Haynes and Boone, LLP

    2323 Victory Avenue, Suite 700

    Dallas, Texas 75219-7673

    (214) 651-5000

     

     

     


    SCHEDULE 13G

    CUSIP No. 92244V104

     

      1    

      Name of Reporting Persons

     

      Mei Mei Hu

      2  

      Check the appropriate box if a member of a Group (see instructions)

     

      (a)  ☐        (b)  ☐

      3  

      Sec Use Only

     

      4  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5    

      Sole Voting Power

     

      73,584,813 (1)

       6  

      Shared Voting Power

     

      4,212,495 (2)

       7  

      Sole Dispositive Power

     

      10,480,128 (3)

       8  

      Shared Dispositive Power

     

      271,655 (4)

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      77,797,308 (1) (2)

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

      ☐

    11  

      Percent of class represented by amount in row (9)

     

      69.5% (5)

    12  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Includes (i) 5,518,961 shares of Class B common stock, par value $0.0001 per share of the Issuer (the “Class B Stock”) owned by the Reporting Person, (ii) 3,370,620 shares of Class B Stock underlying a stock option (the “Class B Options”) owned by the Reporting Person, (iii) 1,590,547 shares of Class A Stock underlying a stock option (the “Class A Options”) owned by the Reporting Person, (iv) 17,500 shares of Class A Stock owned by the Reporting Person’s spouse, (v) 3,955,512 shares of Class B Stock owned by the Reporting Person’s spouse, (vi) 2,346,709 shares of Class A Stock underlying Class A Options owned by the Reporting Person’s spouse, (vii) 2,991,835 shares of Class B Stock underlying Class B Options owned by the Reporting Person’s spouse, (viii) 271,655 shares of Class A Stock owned by Blackfoot Healthcare Ventures LLC, (ix) 51,593,454 shares of Class A Stock owned by United Biomedical, Inc., and (x) 1,928,020 shares of Class A Stock underlying a warrant owned by United Biomedical, Inc. Class B Stock is convertible to Class A Stock on a one-for-one basis and has no expiration date.

    (2)

    Includes 4,212,495 shares of Class A Stock owned by United Biomedical, Asia Inc.

    (3)

    Includes (i) 5,518,961 shares of Class B Stock owned by the Reporting Person, (ii) 3,370,620 shares of Class B Stock underlying Class B Options owned by the Reporting Person, and (iii) 1,590,547 shares of Class A Stock underlying Class A Options owned by the Reporting Person.

    (4)

    Includes 271,655 shares of Class A Stock owned by Blackfoot Healthcare Ventures LLC.

    (5)

    Based upon 111,966,892 shares of Class A common stock, par value $0.0001 per share, of the Issuer (the “Class A Stock”) outstanding as of March 24, 2022, as disclosed in the Issuer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, that was filed on March 24, 2022, by the Issuer with the U.S. Securities and Exchange Commission.


    Item 1.

     

      (a)

    Name of Issuer:

    Vaxxinity, Inc. (the “Issuer”)

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    1717 Main St., Suite 3388, Dallas, Texas 75201.

     

    Item 2.

     

    (a)

    Name of Person Filing:

    This statement is filed by and on behalf of Mei Mei Hu (referred herein as the “Reporting Person”). Pursuant to a voting agreement dated October 1, 2021, by and among various parties including the Reporting Person, the Reporting Person’s spouse, United Biomedical, Inc. (“UBI”), and Blackfoot Healthcare Ventures LLC (the “Voting Agreement”), the Reporting Person shall have the exclusive right to vote the shares of Class A Stock that are held by the Reporting Person, the Reporting Person’s spouse, UBI and Blackfoot Healthcare Ventures LLC (“Blackfoot”), in the Reporting Person’s sole discretion, on all matters submitted to a vote of the stockholders of the Issuer. The Reporting Person disclaims beneficial ownership of the shares of Class A Stock held directly by the Reporting Person’s spouse, Blackfoot, UBI, and United Biomedical, Asia Inc.

    The Reporting Person declares that none of the filing of this statement or anything herein or the Voting Agreement shall be construed as an admission that the Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person under the Voting Agreement or otherwise) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

     

    (b)

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office the Reporting Person is 1717 Main St., Suite 3388, Dallas, Texas 75201.

     

    (c)

    Citizenship:

    See Item 4 on the cover page(s) hereto.

     

    (d)

    Title and Class of Securities:

    Class A Common Stock, par value $0.0001 per share (“Class A Stock”)

     

    (e)

    CUSIP No.:

    92244V104


    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under Section 15 of the Act;
    (b)    ☐    Bank as defined in Section 3(a)(6) of the Act;
    (c)    ☐    Insurance company as defined in Section 3(a)(19) of the Act;
    (d)    ☐    Investment company registered under Section 8 of the Investment Company Act of 1940;
    (e)    ☐    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
    (j)    ☐    A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
    (k)    ☐    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4.

    Ownership

     

    (a)

    Amount Beneficially Owned as of the time of filing:    See Item 9 on the cover pages(s) hereto.

     

    (b)

    Percent of Class as of the time of filing:    See Item 11 on the cover page(s) hereto.

     

    (c)

    As of the time of filing, number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote:    See Item 5 on the cover pages hereto.

     

      (ii)

    Shared power to vote or to direct the vote: See Item 6 on the cover pages hereto.

     

      (iii)

    Sole power to dispose or to direct the disposition of: See Item 7 on the cover pages hereto.

     

      (iv)

    Shared power to dispose or to direct the disposition of: See Item 8 on the cover pages hereto.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owners of more than five percent of the class of securities, check the following  ☐.

     

    Item 6.

    Ownership of more than Five Percent on Behalf of Another Person.

    Not applicable

     

    Item 7.

    Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

    Not applicable


    Item 8.

    Identification and classification of members of the group.

    Not applicable

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable

     

    Item 10.

    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: April 27, 2022

     

    /s/ MEI MEI HU

    MEI MEI HU
    Get the next $VAXX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VAXX

    DatePrice TargetRatingAnalyst
    9/8/2023$7.00Outperform
    Robert W. Baird
    4/27/2022In-line
    Evercore ISI
    12/29/2021$18.00Buy
    Jefferies
    12/7/2021$18.00Buy
    Jefferies
    12/6/2021$21.00Buy
    B of A Securities
    More analyst ratings

    $VAXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Vaxxinity Inc. (Amendment)

      SC 13G/A - Vaxxinity, Inc. (0001851657) (Subject)

      2/12/24 5:02:01 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Vaxxinity Inc. (Amendment)

      SC 13G/A - Vaxxinity, Inc. (0001851657) (Subject)

      2/12/24 5:02:04 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Vaxxinity Inc. (Amendment)

      SC 13G/A - Vaxxinity, Inc. (0001851657) (Subject)

      2/7/24 4:35:42 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VAXX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine

      UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living. Data demonstrates target engagement and immunogenicity of the active immunotherapy UB-312 targeting pathological alpha-synuclein. CAPE CANAVERAL, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (OTC:VAXX), a U.S. company pioneering the development of a new class of medicines known as AIMs (active immunotherapy medicines), announced today that Nature Medicine has published groundbreaking exploratory data from the Company's Phase 1 clinical trial of UB-312 in patients with Parkinson's disease (PD). The succes

      6/20/24 6:00:00 AM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxxinity Issues Shareholder Letter

      CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. ("Vaxxinity", "we", "us" or the "Company") (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced issued a letter to shareholders from its Co-founder and Executive Chairman, Lou Reese and Chief Executive Officer, Mei Mei Hu. To Shareholders of Vaxxinity, Inc.: Earlier today, we announced that we are delisting and deregistering our shares. A few weeks from now, we will no longer be publicly traded on the NASDAQ exchange. It is important to share why we made this decision to "go dark" and why we believe it is in the best interests of the company and our shareholders over

      4/19/24 6:53:35 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

      CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. ("Vaxxinity", "we", "us" or the "Company") (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced its intention to voluntarily delist from the Nasdaq Global Market ("Nasdaq") and to deregister its Class A common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and suspend its reporting obligations under Section 15(d) of the Exchange Act. On February 9, 2024, the Company received a notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC indicating that the Company was no longer

      4/19/24 4:27:16 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VAXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $VAXX
    SEC Filings

    See more
    • SEC Form 4 filed by Ray Sumita

      4 - Vaxxinity, Inc. (0001851657) (Issuer)

      4/29/24 4:15:15 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Paula Molina Rene

      4 - Vaxxinity, Inc. (0001851657) (Issuer)

      11/3/23 4:31:37 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Powchik Peter

      4 - Vaxxinity, Inc. (0001851657) (Issuer)

      10/11/23 9:42:02 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Vaxxinity Inc.

      15-12G - Vaxxinity, Inc. (0001851657) (Filer)

      5/9/24 4:24:53 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14C filed by Vaxxinity Inc.

      DEF 14C - Vaxxinity, Inc. (0001851657) (Filer)

      5/9/24 4:09:43 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Vaxxinity Inc.

      EFFECT - Vaxxinity, Inc. (0001851657) (Filer)

      5/3/24 12:15:22 AM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VAXX
    Leadership Updates

    Live Leadership Updates

    See more
    • Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director

      Appointment adds Dr. Powchik's experience in the development of marketed immunotherapeutics to Vaxxinity's leadership team CAPE CANAVERAL, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, announced that Peter Powchik, M.D., will join Vaxxinity's leadership team as Executive Vice President, Global Scientific Director starting October 1, 2023. He will remain as a member of Vaxxinity's board of directors. Peter will oversee the overall scientific direction of Vaxxinity's platform and programs, and lead the development efforts at Vaxxinity. "Get ready for the next wave of innovative drug science at V

      7/27/23 4:30:36 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida

      Appointment of new directors bring diversity, balance and relevant industry expertise to Vaxxinity Establishment of Frontier Exploration Laboratories ("VaxxLabs") in Cape Canaveral, Fla., as corporate headquarters CAPE CANAVERAL, Fla., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced new appointments to the Board of Directors and the relocation of its corporate headquarters to Cape Canaveral, Fla. "Today's announcements reflect the strength of Vaxxinity's science and people and further equip us to achieve key research and commercial milestones as we prepare to launch our fir

      2/1/23 7:40:51 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxxinity Appoints Dr. Peter Powchik to Board of Directors

      DALLAS, March 21, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines for chronic diseases, today announced that Peter Powchik, M.D. is joining its Board of Directors and will be retiring as Vaxxinity's Executive Vice President, Research & Development. This transition will be effective March 31, 2022 and will increase the size of the Board to seven. "Peter is a rockstar of drug development who has contributed to the approval of over half a dozen new drugs that help patients to this day. We are fortunate to have him joining our Board where we may continue to leverage his considerable expertise to dev

      3/21/22 7:00:00 AM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VAXX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Robert W. Baird initiated coverage on Vaxxinity with a new price target

      Robert W. Baird initiated coverage of Vaxxinity with a rating of Outperform and set a new price target of $7.00

      9/8/23 7:38:37 AM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evercore ISI initiated coverage on Vaxxinity

      Evercore ISI initiated coverage of Vaxxinity with a rating of In-line

      4/27/22 9:03:26 AM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Vaxxinity with a new price target

      Jefferies resumed coverage of Vaxxinity with a rating of Buy and set a new price target of $18.00

      12/29/21 7:23:06 AM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care